Study of Efficacy and Safety of MEXIDOL® in Ischemic Stroke Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.
Also called NCT02793687
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 150 participants
- Sponsor
- Registry
-
NCT02793687
-
- Other papers using this trial's data
- [Efficacy and safety of mexidol across age groups in the acute and early recovery stages of hemispheric ischemic stroke (results of additional sub-analysis of a randomized double blind multicenter placebo-controlled study, in parallel groups trial EPICA)]
- [Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA)]
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Russia
- Registry status
- Completed
Technical summary
Registry record NCT02793687. Randomized; double masking; primary purpose treatment. Start 2015-03-06 (actual); primary completion 2016-05-27 (actual). Results posted on 2025-02-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Efficacy and Safety of MEXIDOL® in Ischemic Stroke Therapy
- Acronym
- EPICA
- Condition
- Ischemic Stroke
- Intervention (Drug)
- Mexidol
- Intervention (Other)
- Placebo
- Lead sponsor
- Pharmasoft
Record details
- Record id
cardio:ct-nct02793687- Content hash
22b97365421a59b5a5752b76a566440c211bd759931b9059955979f432997e3d